

A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma

Submission date 30/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 26/10/2015	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Andrew K Burroughs

Contact details
Department of Liver Medicine & Transplantation
Royal Free Hampstead NHS Trust
Pond Street
Hampstead
London
United Kingdom
NW3 2QG

Additional identifiers

Protocol serial number
N0256159469

Study information

Scientific Title

A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma

Study objectives

Which is the best treatment in terms of survival of patients diagnosed with unresectable unifocal hepatocellular carcinoma (HCC) less than 3 cm in diameter treated with percutaneous ethanol injection or transarterial particle embolisation?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised parallel-group study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cancer: Liver

Interventions

Percutaneous ethanol injection or transarterial particle embolisation

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ethanol

Primary outcome(s)

Survival of patient after treatment of unresectable, unifocal, small (3 cm) hepatocellular carcinoma

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/07/2006

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

31/07/2003

Date of final enrolment

31/07/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Free Hampstead NHS Trust

London

United Kingdom

NW3 2QG

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type

Government

Funder Name

The Royal Free Hampstead NHS Trust (UK)

Funder Name

NHS R&D Support Funding

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration